ClinicalTrials.gg
TerminatedNCT01636960Updated Aug 8, 2018Results posted

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

A Phase 1 interventional study of PegIFN alfa-2b in Malignant Melanoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing peginterferon alfa-2b in Melanoma — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Melanoma.

Enrollment
14th of 14
9 · median 36
Started
2012
with 2 others
Phase 1
5 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing peginterferon alfa-2b in Melanoma, this one is the 14th largest by enrollment, is one of 3 that started in 2012, is one of 5 in phase 1, and was the 10th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 14 studies testing peginterferon alfa-2b in Melanoma is open now. The open studies under Melanoma, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing peginterferon alfa-2b in Melanoma as a file.
02

Study summary

This is a study to evaluate the safety and tolerability of peginterferon alfa-2b (PegIFN alfa-2b) as adjuvant treatment in Japanese participants with malignant melanoma after definitive surgical resection including complete lymphadenectomy. Participants on this study will initially receive PegIFN alfa-2b for 8 weeks (Induction Phase) and then may continue to receive PegIFN alfa-2b (Maintenance Phase) as long as they are experiencing clinical benefit (Up to 252 weeks). The primary hypothesis is that peginterferon alfa-2b administered on a weekly basis is safe and tolerated.

Read the detailed description

The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage II or III melanoma
  • Primary melanoma completely excised
  • Full lymphadenectomy within 84 days prior to initiation of study treatment
  • (ECOG) Performance Status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Ocular melanoma or melanoma of the mucous membranes
  • Evidence of distant or non-regional lymph node
  • In-transit melanoma
  • Previously treated with interferon alpha/beta, chemotherapy, hormonal therapy, radiotherapy or immunotherapy/vaccine for melanoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Participants receiving PegIFN alfa-2b

    Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).

    Biological: PegIFN alfa-2b

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase

    A DLT was an event (clinical or laboratory) that resulted in a change in the given dose.

    Time frame: From first dose to end of induction phase; up to 8 Weeks

Secondary outcomes

  1. Safety: Number of Participants Experiencing Adverse Events (AEs)

    An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

    Time frame: From first dose through follow-up; up to 265 Weeks

  2. Number of Participants Discontinuing Study Drug Because of AEs

    An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

    Time frame: From first dose to last dose of treatment; up to 260 Weeks

07

Results

Posted Feb 11, 2015
Limitations and caveats
The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.

Participant flow

This study enrolled Japanese participants with Stage II or III malignant melanoma who had undergone surgical resection and lymphadenectomy.

Induction Phase
Participant flow — Induction Phase
MilestoneParticipants Receiving PegIFN Alfa-2b
Started9
Completed7
Not completed2
Withdrew: Adverse event2
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneParticipants Receiving PegIFN Alfa-2b
Started7
Completed0
Not completed7
Withdrew: Continued drug after regulatory approval3
Withdrew: Adverse event3
Withdrew: Progressive disease1

Outcome measures

PrimaryNumber of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase

A DLT was an event (clinical or laboratory) that resulted in a change in the given dose.

Time frame:
From first dose to end of induction phase; up to 8 Weeks
Reported as:
Number · Participants
Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase
ParticipantsParticipants Receiving PegIFN Alfa-2b
Number of Participants Experiencing Dose-limiting Toxicities (DLTs) - Induction Phase2
SecondarySafety: Number of Participants Experiencing Adverse Events (AEs)

An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

Time frame:
From first dose through follow-up; up to 265 Weeks
Reported as:
Number · Participants
Safety: Number of Participants Experiencing Adverse Events (AEs)
ParticipantsParticipants Receiving PegIFN Alfa-2b
Safety: Number of Participants Experiencing Adverse Events (AEs)9
SecondaryNumber of Participants Discontinuing Study Drug Because of AEs

An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.

Time frame:
From first dose to last dose of treatment; up to 260 Weeks
Reported as:
Number · Participants
Number of Participants Discontinuing Study Drug Because of AEs
ParticipantsParticipants Receiving PegIFN Alfa-2b
Number of Participants Discontinuing Study Drug Because of AEs5

Adverse events

Collected over From first dose through follow-up; up to 265 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Receiving PegIFN Alfa-2b—0/9 (0%)9/9 (100%)
Most frequent other events
Showing 10 of 92
Most frequent other events
EventParticipants Receiving PegIFN Alfa-2b
PyrexiaGeneral disorders9/9
Neutrophil count decreasedInvestigations9/9
White blood cell count decreasedInvestigations9/9
ArthralgiaMusculoskeletal and connective tissue disorders9/9
Alanine aminotransferase increasedInvestigations8/9
Aspartate aminotransferase increasedInvestigations8/9
NauseaGastrointestinal disorders6/9
ChillsGeneral disorders6/9
Injection site reactionGeneral disorders6/9
MalaiseGeneral disorders6/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants Receiving PegIFN Alfa-2b
Mean43.3 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving PegIFN Alfa-2b
Female4
Male5
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol. 2016 Oct;43(10):1146-1153. doi: 10.1111/1346-8138.13338. PubMed 27087489 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2012 to primary completion in Mar 2014, 15 months.

Results were first posted in Feb 2015, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2012
First posted
Jul 10, 2012
StartActual
Dec 25, 2012
Primary completionActual
Mar 26, 2014
CompletionActual
Nov 4, 2015
Results first posted
Feb 11, 2015
Last update
Aug 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01636960
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Dec 25, 2012
Primary completion
Mar 26, 2014
Completion
Nov 4, 2015
Results posted
Feb 11, 2015
Last update
Aug 8, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion